Literature DB >> 28420501

Bioinformatics analysis of gene expression profiles in B cells of postmenopausal osteoporosis patients.

Min Ma1, Shulin Luo1, Wei Zhou1, Liangyu Lu1, Junfeng Cai2, Feng Yuan1, Feng Yin3.   

Abstract

OBJECTIVE: The aim of this study was to gain a better understanding of the molecular mechanisms and identify more critical genes associated with the pathogenesis of postmenopausal osteoporosis (PMOP).
MATERIALS AND METHODS: Microarray data of GSE13850 were download from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were identified either in B cells from postmenopausal female nonsmokers with high bone mineral density (BMD) compared with those with low BMD (defined as DEG1 group) or in B cells from postmenopausal female smokers with high BMD compared with postmenopausal female nonsmokers with high BMD (defined as DEG2 group). Gene ontology and immune-related functional enrichment analysis of DEGs were performed. Additionally, the protein-protein interaction network of all DEGs was constructed and subnetworks of the hub genes were extracted.
RESULTS: A total of 51 DEGs were identified in the DEG1 group, including 30 up- and 21 downregulated genes. Besides, 86 DEGs were identified in the DEG2 group, of which 46 were upregulated and 40 were downregulated. Immune enrichment analysis showed DEGs were mainly enriched in functions of CD molecules and chemokines and receptor, and the upregulated gene interleukin 4 receptor (IL-4R) was significantly enriched. Moreover, guanine nucleotide-binding protein G (GNAI2), filamin A alpha (FLNA), and transforming growth factor-β1 (TGFB1) were hub proteins in the protein-protein interaction network.
CONCLUSION: IL-4R, GNAI2, FLNA, and TGFB1 may be potential target genes associated with the pathogenesis of PMOP. In particular, FLNA, and TGFB1 may be affected by smoking, a risk factor of PMOP.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  differentially expressed genes; gene ontology; postmenopausal osteoporosis; smoking

Mesh:

Substances:

Year:  2017        PMID: 28420501     DOI: 10.1016/j.tjog.2016.04.038

Source DB:  PubMed          Journal:  Taiwan J Obstet Gynecol        ISSN: 1028-4559            Impact factor:   1.705


  7 in total

Review 1.  Artificial intelligence, osteoporosis and fragility fractures.

Authors:  Uran Ferizi; Stephen Honig; Gregory Chang
Journal:  Curr Opin Rheumatol       Date:  2019-07       Impact factor: 5.006

2.  Investigation of candidate genes and mechanisms underlying postmenopausal osteoporosis using bioinformatics analysis.

Authors:  Xiaozhong Zhu; Zhiyuan Wang; Yanxun Zhao; Chao Jiang
Journal:  Mol Med Rep       Date:  2017-11-14       Impact factor: 2.952

3.  Identification of gene biomarkers in patients with postmenopausal osteoporosis.

Authors:  Chenggang Yang; Jing Ren; Bangling Li; Chuandi Jin; Cui Ma; Cheng Cheng; Yaolan Sun; Xiaofeng Shi
Journal:  Mol Med Rep       Date:  2018-12-12       Impact factor: 2.952

4.  Systemic immune-inflammation index acts as a novel diagnostic biomarker for postmenopausal osteoporosis and could predict the risk of osteoporotic fracture.

Authors:  Hong Fang; Hanqing Zhang; Zhi Wang; Zhongming Zhou; Yunjun Li; Lin Lu
Journal:  J Clin Lab Anal       Date:  2019-08-19       Impact factor: 2.352

5.  Identification of Potential Osteoporosis miRNA Biomarkers Using Bioinformatics Approaches.

Authors:  Wei Lu; Qiang Wang; Yi Xue; Jie Gu; Ping Yao; Yufan Ge; Yiming Miao; Jun Chen
Journal:  Comput Math Methods Med       Date:  2021-11-02       Impact factor: 2.238

6.  UBE2E3 regulates cellular senescence and osteogenic differentiation of BMSCs during aging.

Authors:  Yalin Liu; Guangping Cai; Peng Chen; Tiejian Jiang; Zhuying Xia
Journal:  PeerJ       Date:  2021-11-18       Impact factor: 2.984

7.  Identification of ferroptosis-associated biomarkers for the potential diagnosis and treatment of postmenopausal osteoporosis.

Authors:  Yunxiang Hu; Jun Han; Shengqiang Ding; Sanmao Liu; Hong Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.